NovaBay Pharmaceuticals (NYSE:NBY – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.95) EPS for the quarter, reports. NovaBay Pharmaceuticals had a negative return on equity of 121.42% and a negative net margin of 65.46%. The firm had revenue of $3.73 million for the quarter.
NovaBay Pharmaceuticals Stock Down 5.9 %
NYSE NBY traded down $0.01 during trading on Thursday, reaching $0.10. 1,981,271 shares of the company’s stock were exchanged, compared to its average volume of 3,657,216. The company has a 50 day moving average price of $0.15 and a two-hundred day moving average price of $0.26. NovaBay Pharmaceuticals has a 1 year low of $0.10 and a 1 year high of $1.95.
Institutional Trading of NovaBay Pharmaceuticals
A hedge fund recently bought a new stake in NovaBay Pharmaceuticals stock. Armistice Capital LLC purchased a new position in shares of NovaBay Pharmaceuticals, Inc. (NYSE:NBY – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 718,768 shares of the company’s stock, valued at approximately $147,000. Armistice Capital LLC owned about 11.01% of NovaBay Pharmaceuticals at the end of the most recent reporting period. 23.25% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Get Our Latest Research Report on NovaBay Pharmaceuticals
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.
Further Reading
- Five stocks we like better than NovaBay Pharmaceuticals
- Investing in the High PE Growth Stocks
- 3 Value Stocks Too Small For Buffett’s Portfolio
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- Where Do I Find 52-Week Highs and Lows?
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
